## Walkboost Group Overview



Walkboost Ltd was established in 2003 and consists of 3 trading companies; all of them are based in Bolton. The Group is owned 50:50 by the Day Lewis Group and the Cohens Group employing c.100 staff across two sites.



Maxearn Ltd is a parallel import re-packaging company established in 2001 with an annual turnover of c.£2million, employing in excess of 65 staff. Its business is to repack imported branded medicines from within the European Union on behalf of UK pharmaceutical distributors into English packaging in accordance with licences granted by the UK Government's medicine safety watchdog, the Medicine and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMEA). Key customers are the Day Lewis Group, Trident Pharmaceuticals Ltd and OTC Direct Ltd.



Eaststone Ltd was established 2007 and acquired by Walkboost Ltd in October 2015. It is a "Specials" medicine manufacturer with an annual turnover of c.£5million, employing in excess of 35 staff.

- Specials are unlicenced medicines, permitted to be sold by the Medicines and Healthcare products Regulatory Agency (MHRA) when no usual licenced medicine is suitable for a particular patient.
- They are frequently prescribed for elderly patients and for children who cannot swallow tablets or who are allergic to one or more of the ingredients of the normal licenced product.
- Specials are usually bespoke medicines, made for the individual patient, so are not normally available from a pharmacy wholesaler.
- If an order is received by 5.00pm, we will manufacture the bespoke medicine and deliver it to the pharmacy customer the following day.

The customer base comprises of over 170 different customers including independent pharmacies, groups and wholesalers.

## **Quadrant Pharmaceuticals Ltd**

Quadrant Pharmaceuticals Ltd was established in 2003 and is currently a non-trading company within the group which holds and maintains the parallel import product licences required Maxearn Ltd and other pharmaceutical companies in order for them to repackage pharmaceuticals for redistribution throughout the UK.